Erbitux effective in cancer trial

Imclone announced that a late-stage trial shows that Erbitux combined with radiation therapy can prevent the spread of head and neck cancer. The drug proved statistically significant in both survival and progression-free survival among patients with head and neck cancer. The drug has already been approved for colorectal cancer.

"Head and neck cancer remains a disease with too few treatment options and no new therapeutic product approvals in over a decade," said Eric K. Rowinsky, chief medical officer of ImClone. "We look forward to discussing the next steps toward a regulatory filing with the FDA."

- read this story from the AP for more

ALSO: Wall Street financier Carl Icahn has indicated his intention to increase his stake in Imclone. He currently owns 6 percent of the company's stock.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.